HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Voriconazole

HCID 71616
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
137234-62-9
Standard SMILES
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
InChIKey
BCEHBSKCWLPMDN-MGPLVRAMSA-N
Molecular formula
C16H14F3N5O
Average molar mass
349.31 g/mol
Monoisotopic mass
349.11504457

Overview

Voriconazole is a triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4. It has a role as a P450 inhibitor. It is a tertiary alcohol, a difluorobenzene, a member of pyrimidines, a conazole antifungal drug and a triazole antifungal drug.

Names & identifiers

Preferred name
Voriconazole
IUPAC
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
English name
Voriconazole-d3
Molecular formula
C16H14F3N5O
Molecular weight
349.31

Names & synonyms

Voriconazole137234-62-9Vfend(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-olUK-109496Voriconazol(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-olVoriconazolumUK-109,496UK 109496JFU09I87TRNSC-759888
Show more names
3R)-2-(2VORICONAZOLE-D3(±)-VoriconazoleVoriconazole PI-6(2R,3R)-VoriconazoleFluconazole Intermediate 2Voriconazole Intermediate IIIntermediate 2 of voriconazole4-triazol-1-yl)-2-butanol (RaceMic Voriconazole)4-Difluorophenyl)-3-(5-fluoro-4-pyriMidinyl)-1-(1H-1
DTXSID5046485(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanolCHEBI:10023(alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanolDTXCID3026485UK109496RefChem:56222UK109,496

Properties

Computed structural properties

XLogP
1.5
Topological polar surface area
76.7 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
8
Rotatable bonds
5
Heavy atoms
25
Formal charge
0
Complexity
448

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Anti infectives for systemic use -> Antibacterials for systemic use

PesticidesFungicides
LogP · 2 items

1

1.7

Solubility · 2 items

Low

9.78e-02 g/L

Human Drugs · 6 items

Breast Feeding; Lactation; Milk, Human; Antifungal Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point127 - 130 °C
Physical DescriptionSolid

Physicochemical properties

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (99.2%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P264, P270, P273, P280, P301+P316, P318, P319, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 118 reports by companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationHazard Traits - Carcinogenicity
Hazard Classes and CategoriesAcute Tox. 3 (99.2%)

Toxicology

Hepatotoxicity · 1 item

Transient elevations in serum aminotransferase levels occur in 11% to 19% of patients on voriconazole. These elevations are usually asymptomatic and self-limited, but approximately 1% of patients require discontinuation of voriconazole because of ALT elevations. Clinically apparent hepatotoxicity is uncommon, but may be more frequent than with fluconazole and itraconazole. The injury arises within the first month of therapy and the pattern of serum enzyme elevations has been variable from cholestatic to hepatocellular. Several cases of acute liver failure attributed to voriconazole have been reported. Immunoallergic features and autoantibodies are uncommon. Recovery upon stopping therapy generally takes 6 to 10 weeks but, in some cases, the time to complete resolution may be prolonged.

Carcinogen Classification · 5 items

Voriconazole

Group 1: Carcinogenic to humans

Volume 137: (2026) Hydrochlorothiazide, Voriconazole, and Tacrolimus

Chemistry & industry

Pharmacology

ATC Code · 4 items

J02AC03

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

J02AC03

Protein BindingVoriconazole is 58% bound to plasma proteins.
PharmacodynamicsVoriconazole is a fungistatic triazole antifungal used to treat infections by inhibiting fungal growth. It is known to cause hepatotoxic and photosensitivity reactions in some patients.
Mechanism of Action · 1 item

Voriconazole is used to treat fungal infections caused by a variety of organisms but including _Aspergillus spp._ and _Candida spp_. Voriconazole is a triazole antifungal exhibiting fungistatic activity against fungal pathogens. Like other triazoles, voriconazole binds to 14-alpha sterol demethylase, also known as CYP51, and inhibits the demethylation of lanosterol as part of the ergosterol synthesis pathway in yeast and other fungi. The lack of sufficient ergosterol disrupts fungal cell membrane function and limits fungal cell growth. With fungal growth limited, the host's immune system is able to clear the invading organism.

Biological Half-LifeVoriconazole follows non-linear kinetics and has a terminal half-life of elimination which is dose-dependent.
Metabolism/Metabolites · 2 items

Voriconazole undergoes extensive hepatic metabolism through cytochrome enzymes CYP2C9, CYP2C19, and CYP3A4. CYP2C19 mediates N-oxidation with an apparent Km of 14 μM and an apparent Vmax of 0.22 nmol/min/nmol CYP2C19. Voriconazole N-oxide is the major circulating metabolite, accounting for 72% of radiolabeled metabolites found. CYP3A4 contributes to N-oxidation with a Km of 16 μM and Vmax of 0.05 nmol/min/nmol CYP3A4 as well as 4-hydroxylation with a Km of 11 μM and a Vmax of 0.10 nmol/min/nmol CYP3A4. CYP3A5 and CYP3A7 provide minor contributions to N-oxidation and 4-hydroxylation. The N-oxide and 4-hydroxylated metabolites undergo glucuronidation and are excreted through the urine with other minor glucuronidated metabolites.

Voriconazole has known human metabolites that include Voriconazole N-Oxide and Hydroxymethyl Voriconazole.

Related reactions

18 records
New reaction record
HRID 489474 reaction equation
HRID 489474As reactant
HRID 1006649 reaction equation
HRID 1006649As reactant
HRID 1051188 reaction equation
HRID 1051188As product
HRID 1099517 reaction equation
HRID 1099517As reactant
HRID 1099518 reaction equation
HRID 1099518As productAs reactant
HRID 1099519 reaction equation
HRID 1099519As reactant
HRID 1099520 reaction equation
HRID 1099520As product
HRID 1099521 reaction equation
HRID 1099521As product
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
137234-62-9、188416-29-7
PubChem CID
71616
DTXSID
DTXSID201019420
ChEMBL
CHEMBL638
ChEBI
CHEBI:10023
UNII
JFU09I87TR、USG4B1CD29
EC Number
629-701-5、941-833-8
Nikkaji
J709.476K
Boiling point
508.6 · 508.6±60.0 °C(Predicted)
Density
1.42 · 1.42±0.1 g/cm3(Predicted)
storage temp.
2 · Storage temp. 2-8°C
pka
11.54 · 11.54±0.29(Predicted)
form
Solid
color
White to off-white
InChI
InChI=1/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/s3
InChIKey
BCEHBSKCWLPMDN-NLBNCHMPNA-N
SMILES
C[C@@H]([C@@](CN1C=NC=N1)(C1C(F)=CC(F)=CC=1)O)C1C(F)=CN=CN=1 |&1:1,2,r|
FDA UNII
4 B1CD29 · USG4B1CD29
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

2026 online

2024

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Voriconazole

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319-H335
Precautionary statements
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501
FDA Pharmacological Classification · 6 items

JFU09I87TR

VORICONAZOLE

Established Pharmacologic Class [EPC] - Azole Antifungal

Chemical Structure [CS] - Azoles

Mechanisms of Action [MoA] - Cytochrome P450 3A4 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C19 Inhibitors

MeSH Pharmacological Classification · 3 items

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.

Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.

Absorption, Distribution and Excretion · 4 items

The oral bioavailability is estimated to be 96% in healthy adults. Population pharmacokinetic studies report a reduced bioavailability pediatric patients with a mean of 61.8% (range 44.6–64.5%) thought to be due to differences in first-pass metabolism or due to differences in diet. Of note, transplant patients also have reduced bioavailability but this is known to increase with time after transplantation and may be due in part to gastrointestinal upset from surgery and some transplant medications. Tmax is 1-2 hours with oral administration. When administered with a high-fat meal Cmax decreases by 34% and AUC by 24%. pH does not have an effect on absorption of voriconazole. Differences in Cmax and AUC have been observed between healthy adult males and females with Cmax increasing by 83% and AUC by 113% although this has not been observed to significantly impact medication safety profiles.

Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.

The estimated volume of distribution of voriconazole is 4.6 L/kg. Population pharmacokinetic studies estimate the median volume of distribution to be 77.6 L with the central compartment estimated at 1.07 L/kg Voriconazole is known to achieve therapeutic concentrations in many tissues including the brain, lungs, liver, spleen, kidneys, and heart.

The clearance of voriconazole is estimated to be a mean of 5.25-7 L/h in healthy adults for the linear portion of the drug's kinetics.

Cellular LocationsCytoplasm

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >100
Use ClassificationFungicides
Applications · 2 items

DescriptionVoriconazole-d3 is an Ergosterol biosynthesis inhibitor and a labeled form of Voriconazole. This mono triazole antifungal agent inhibits the growth of Candida, Cryptococcus, and Aspergillus species. Studies suggest that Voriconazole-d3 can be synthesized by modifying the structure of fluconazole. This antifungal agent functions by inhibiting cytochrome P450 dependent 14-α-sterol demethylase, which is responsible for the biosynthesis of Ergosterol. Furthermore, Voriconazole-d3 inhibits fungal growth, cell wall thinning, and cell membrane degradation.

UsesVoriconazole is a triazole antifungal agent used primarily in the treatment or prevention of aspergillosis and candidal infections. However, its therapy may cause transient, asymptomatic serum aminotransferase elevations, and it is also a well-known cause of acute drug-induced liver injury.